Journal of Vaccine Research 2024, Vol.14, No.2, 54-64 http://medscipublisher.com/index.php/jvr 58 Despite these successes, challenges remain. Vaccine coverage is not uniform across all regions and populations, leading to pockets of lower immunity and higher antibiotic use. Future directions include increasing vaccine coverage, developing new vaccines for resistant pathogens, and integrating vaccination strategies with other AMR mitigation efforts (Jansen et al., 2018; Tagliabue and Rappuoli, 2018; Costanzo and Roviello, 2023). 4.2 Europe Europe has implemented comprehensive vaccination strategies and policies aimed at reducing the burden of infectious diseases and AMR. The European Union and individual countries have prioritized the development and deployment of vaccines as part of their AMR action plans (Tagliabue and Rappuoli, 2018; Jansen et al., 2021). Vaccination has played a crucial role in reducing AMR in Europe. For instance, the introduction of pneumococcal vaccines has led to a significant decline in antibiotic-resistant Streptococcus pneumoniae infections. Similar trends have been observed with other vaccines, contributing to a reduction in antibiotic use and resistance (Jansen and Anderson, 2018; Jansen et al., 2021). Barriers to the effective implementation of vaccination programs in Europe include vaccine hesitancy, logistical challenges, and disparities in healthcare access. Solutions involve public education campaigns to increase vaccine acceptance, improved vaccine distribution networks, and policies to ensure equitable access to vaccines (Jansen et al., 2018; Kumar, 2018; Costanzo and Roviello, 2023). 4.3Asia Vaccination programs in Asia vary widely between countries, with some nations having robust programs and others facing significant challenges. Efforts are ongoing to expand vaccine coverage and introduce new vaccines to combat AMR (Micoli et al., 2021; Costanzo and Roviello, 2023). The effectiveness of vaccination programs in Asia has been mixed. While some countries have seen substantial reductions in AMR due to successful vaccination campaigns, others struggle with low coverage and high rates of antibiotic misuse. Challenges include limited healthcare infrastructure, vaccine accessibility, and public awareness (Jansen et al., 2018; Tagliabue and Rappuoli, 2018; Buchy et al., 2019). Future directions for vaccination strategies in Asia include increasing investment in healthcare infrastructure, enhancing public education on the benefits of vaccination, and developing region-specific vaccines to address local AMR challenges. International collaborations and support from global health organizations will be crucial in these efforts (Lipsitch and Siber, 2016; Micoli et al., 2021; Saeed et al., 2023). By examining these global perspectives, it becomes clear that while vaccination strategies have made significant strides in mitigating AMR, ongoing efforts and innovations are essential to overcome existing challenges and further reduce the global burden of antimicrobial resistance. 5 Case Studies 5.1 Application of pneumococcal vaccines in mitigating antimicrobial resistance Vaccines can reduce antibiotic use and thus mitigate the problem of resistance through multiple pathways, including preventing infections by specific pathogens, reducing the severity of symptoms, selecting specific subtypes, and reducing cross-infections (Jit and Cooper, 2020; Ruban and Struch, 2021). For example, pneumococcal vaccines have shown significant potential in reducing antimicrobial resistance (AMR). Andrejko et al. (2021) found that the implementation of pneumococcal conjugate vaccines (PCVs) significantly reduced the resistance of Streptococcus pneumoniae to first-line antibiotics such as penicillin, sulfamethoxazole-trimethoprim, and third-generation cephalosporins. The data show that within ten years after vaccine implementation, penicillin non-susceptibility in Streptococcus pneumoniae decreased by 11.75%, sulfamethoxazole-trimethoprim by 9.77%, and third-generation cephalosporins by 7.5% (Figure 2). The study also pointed out that the phenomenon of replacement by vaccine-targeted serotypes led to lower resistance levels in non-vaccine serotypes, contributing to an overall reduction in resistance (Andrejko et al., 2021). Additionally, the broad economic value of pneumococcal vaccines in controlling AMR has been confirmed, highlighting their importance in public health strategies (Htar et al., 2019; Micoli et al., 2021).
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==